Skip to Main Content

Author Archives: O'Neill Institute

05.22.18

A Literature Review of Public Health Systems Research (PHSR) in Public Health Emergency Preparedness (PHEP)

By O'Neill Institute

Background: To conduct a systematic literature review in order to identify and characterize the PHSR literature produced in the United States in the past ten years in the field of public health emergency preparedness. Methods: Articles were searched in Medline, Embase as well as in the gray literature. Two independent reviewers classified the articles according […]

Categories:
Tags:
Thematic Areas:

05.21.18

Recent Activities

By O'Neill Institute

2014 August 18-19 August 2014 In partnership with the American Cancer Society and the Centro de Estudos sobre Tabaco e Saúde at FIOCRUZ we provided a workshop for government officials and civil society in Brazil to coincide with the release of a joint publication on the Political Economy of Tobacco Control in Brazil. July 9 […]

Categories:
Tags:
Thematic Areas:

05.21.18

ARV-Based HIV Prevention Technologies: Developing the Capacity and Tools to Deliver New Prevention Products

By O'Neill Institute

THE ISSUE IN BRIEF Supported by the Bill & Melinda Gates Foundation, this project examines the delivery and implementation of the use of antiretroviral drugs as a pre-exposure prophylaxis (PrEP) in comprehensive HIV prevention programs. The O’Neill Institute is part of a larger global effort with several partners, which include Imperial College London, the London […]

Categories:
Tags:
Thematic Areas:

05.21.18

Improving Hepatitis C Data and Surveillance

By O'Neill Institute

Hepatitis C (HCV) is a contagious, blood-borne infection that causes inflammation and scarring of the liver. Hepatitis C is the most common blood-borne infection in the U.S. and is the leading cause of cirrhosis, liver cancer, and liver transplantation. In the United States, there are more deaths from Hepatitis C than all of the other […]

Categories:
Tags:
Thematic Areas:

05.21.18

Hepatitis C and Injection Drug Use

By O'Neill Institute

The opioid epidemic in the U.S. is a current public health crisis that stems from high rates of prescribing and misuse of prescription opioid drugs. Opioid drugs, such as oxycodone (e.g. Percocet) or hydrocodone (e.g. Vicodin), are prescribed as painkillers, and have seen a sharp increase in the rate of prescriptions written in the past […]

Categories:
Tags:
Thematic Areas:

05.21.18

Hepatitis C Publications

By O'Neill Institute

New Publication Eliminating Hepatitis C Among People Living with HIV in the United States: Leveraging the Ryan White HIV/AIDS Program to Move Us Forward. Read the article. One in four people living with HIV in the U.S. will acquire hepatitis C within their lifetime. The Ryan White HIV/AIDS Program, as the anchor of the nation’s […]

Categories:
Tags:
Thematic Areas:

05.21.18

Access to Treatment and Care

By O'Neill Institute

“I don’t think people should be living with Hepatitis C. I think they should be cured.” Dr. Jonathan Mermin – Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention May 19, 2016 – National Hepatitis Testing Day 2016 – The White House.   Direct-acting Antiviral (DAAs) drug therapies are now available that reduce […]

Categories:
Tags:
Thematic Areas:

05.21.18

Elimination of Hepatitis C

By O'Neill Institute

Elimination of Hepatitis C in the U.S. would result in the significant reduction of the incidence of the infection – to the point where cases of the infection are rare and sporadic – as a result of deliberate efforts, with ongoing efforts to maintain the zero prevalence. In 2017, HHS released its 2017-2020 Viral Hepatitis […]

Categories:
Tags:
Thematic Areas:

The views reflected in this expert column are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.